Search research articles
Contact Us
Filters
Showing results (151-160 of 290) with videos related to
Page
of 29
Sort By:
The Journal of Biological Chemistry
|
June 16, 2012
The c-Jun N-terminal kinase (JNK)-binding protein (JNKBP1) acts as a negative regulator of NOD2 protein signaling by inhibiting its oligomerization process
Aurore Lecat, Emmanuel Di Valentin, Joan Somja, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD
|
June 30, 2024
Diet Optimization in Inflammatory Bowel Disease: Impact on Disease Relapse and Inflammatory Markers. A 1-year Prospective Trial
Carmen Monica Preda, Doina Istratescu, Maria Nitescu, et al.
Gut
|
October 27, 2020
Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study
Nicolas Pierre, Dominique Baiwir, Vân Anh Huynh-Thu, et al.
Biochemical Pharmacology
|
January 30, 2007
Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling
Marie-Alice Meuwis, Marianne Fillet, Pierre Geurts, et al.
Inflammatory Bowel Diseases
|
November 16, 2016
Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years
Gilles Boschetti, Stephane Nancey, Fady Daniel, et al.
Journal of Crohn'S & Colitis
|
September 24, 2011
Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease
Marco Daperno, Fabiana Castiglione, Lissy de Ridder, et al.
Journal of Crohn'S & Colitis
|
September 7, 2024
Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire
Eman Al Sulais, Edouard Louis, Bernd Bokemeyer, et al.
Clinical Biochemistry
|
May 21, 2008
Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study
Marie-Alice Meuwis, Marianne Fillet, Laurence Lutteri, et al.
Acta Gastro-Enterologica Belgica
|
March 7, 2003
The role of aminosalicylates in the treatment of ulcerative colitis
Gert Van Assche, Filip Baert, Marc De Reuck, et al.
Gastro Hep Advances
|
August 12, 2024
Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, et al.
Page
of 29
Search research articles
Search
Showing results (151-160 of 290) with videos related to
Sort By:
Page
of 29
The Journal of Biological Chemistry
|
June 16, 2012
The c-Jun N-terminal kinase (JNK)-binding protein (JNKBP1) acts as a negative regulator of NOD2 protein signaling by inhibiting its oligomerization process
Aurore Lecat, Emmanuel Di Valentin, Joan Somja, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD
|
June 30, 2024
Diet Optimization in Inflammatory Bowel Disease: Impact on Disease Relapse and Inflammatory Markers. A 1-year Prospective Trial
Carmen Monica Preda, Doina Istratescu, Maria Nitescu, et al.
Gut
|
October 27, 2020
Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study
Nicolas Pierre, Dominique Baiwir, Vân Anh Huynh-Thu, et al.
Biochemical Pharmacology
|
January 30, 2007
Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling
Marie-Alice Meuwis, Marianne Fillet, Pierre Geurts, et al.
Inflammatory Bowel Diseases
|
November 16, 2016
Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years
Gilles Boschetti, Stephane Nancey, Fady Daniel, et al.
Journal of Crohn'S & Colitis
|
September 24, 2011
Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease
Marco Daperno, Fabiana Castiglione, Lissy de Ridder, et al.
Journal of Crohn'S & Colitis
|
September 7, 2024
Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire
Eman Al Sulais, Edouard Louis, Bernd Bokemeyer, et al.
Clinical Biochemistry
|
May 21, 2008
Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study
Marie-Alice Meuwis, Marianne Fillet, Laurence Lutteri, et al.
Acta Gastro-Enterologica Belgica
|
March 7, 2003
The role of aminosalicylates in the treatment of ulcerative colitis
Gert Van Assche, Filip Baert, Marc De Reuck, et al.
Gastro Hep Advances
|
August 12, 2024
Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, et al.
Page
of 29